FBLG
FibroBiologics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.93
−3.99%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -35.3%
- EBIT
- -4.0%
- EPS
- +14.2%
- Free cash flow
- +3.3%
- Operating cash flow
- +1.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +51.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -66.6%
- EBIT
- -21.2%
- Net income
- -67.1%
- EPS
- -22.8%
- Free cash flow
- -37.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026